The potential risk of NAION outweighs the health benefits of GLP-1 drugs

A JAMA Network Open study found a small but increased NAION risk in patients prescribed semaglutide or tirzepatide for type 2 diabetes.

From the articleSemaglutide, Tirzepatide Linked to Small Increase in Eye Disorder Risk | AJMCAlso in GLP-1s and NAION: Do Patients Need a Warning?